-
公开(公告)号：US20240317733A1
公开(公告)日：2024-09-26
申请号：US18449326
申请日：2023-08-14
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubral pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.-
公开(公告)号：US20190300536A1
公开(公告)日：2019-10-03
申请号：US16366710
申请日：2019-03-27
发明人： Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC分类号： C07D487/04 , C07D471/04 , A61K9/20 , A61K9/48
摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
-
公开(公告)号：US20160311814A1
公开(公告)日：2016-10-27
申请号：US15203522
申请日：2016-07-06
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/12 , C07D285/135 , C07D409/12 , C07D307/79 , C07D413/14 , C07D213/82 , C07D333/38 , C07D277/56 , C07D417/14 , C07D409/14 , C07D231/12 , C07D407/12
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号：US20210179603A1
公开(公告)日：2021-06-17
申请号：US17176861
申请日：2021-02-16
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D417/12 , C07D409/12 , C07D307/79 , C07D407/12 , C07D213/82 , C07D333/38 , C07D413/14 , C07D231/14 , C07D333/40 , C07D285/08 , C07D285/135 , C07D231/12 , C07D277/56 , C07D409/14 , C07D413/12 , C07D307/81
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号：US20200377509A1
公开(公告)日：2020-12-03
申请号：US16497141
申请日：2018-03-29
发明人： Seiji MIWATASHI , Yasufumi MIYAMOTO , Koji WATANABE , Yayoi NAKAYAMA , Yuko HITOMI , Jumpei AIDA , Nobuyuki TAKAKURA , Hideki FURUKAWA , Naoyoshi NOGUCHI , Yasuhiro HIRATA , Shizuo KASAl , Toshitake KOBAYASHI , Tsuyoshi MAEKAWA , Satoshi SASAKI , Shigemitsu MATSUMOTO
IPC分类号： C07D491/052 , C07D401/12 , C07D401/14 , C07D211/22
摘要： Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
-
公开(公告)号：US20170001994A1
公开(公告)日：2017-01-05
申请号：US15270863
申请日：2016-09-20
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/12 , C07D285/135 , C07D409/12 , C07D413/12 , C07D407/12 , C07D213/82 , C07D417/14 , C07D333/38 , C07D231/14 , C07D307/79
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
摘要翻译： 其中每个符号如本说明书中所定义，或其盐。
-
公开(公告)号：US20150291577A1
公开(公告)日：2015-10-15
申请号：US14682695
申请日：2015-04-09
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D409/12 , C07D333/38 , C07D407/12 , C07D213/82 , C07D417/12 , C07D307/79
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
摘要翻译： 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。
-
公开(公告)号：US20220340527A1
公开(公告)日：2022-10-27
申请号：US17754118
申请日：2020-09-25
发明人： Yuya OGURO , Makoto KAMATA , Shuhei IKEDA , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Shigemitsu MATSUMOTO , Hirotaka KAMITANI , Takaharu HIRAYAMA , Toshio TANAKA , Hiroshi BANNO , Nobuyuki TAKAKURA , Jinichi YONEMORI , Takuya FUJIMOTO
IPC分类号： C07D211/04 , C07D237/08 , C07D239/26 , C07D405/02
摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
-
公开(公告)号：US20180162853A1
公开(公告)日：2018-06-14
申请号：US15882386
申请日：2018-01-29
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D333/38 , C07D413/14 , C07D407/12 , C07D307/79 , C07D409/12 , C07D417/12 , C07D307/81 , C07D413/12 , C07D409/14 , C07D231/12 , C07D277/56 , C07D285/135 , C07D285/08 , C07D333/40 , C07D231/14 , C07D213/82
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号：US20170029417A1
公开(公告)日：2017-02-02
申请号：US15302405
申请日：2015-04-09
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D231/14 , C07D285/135 , C07D413/14 , C07D307/81 , C07D407/12 , C07D213/82 , C07D333/38 , C07D417/12 , C07D409/12
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
摘要翻译： 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.031 秒)
